Evaluation of coagulogram abnormalities as a risk factor for recurrence of full-thickness macular hole when using autologous conditioned plasma
Year: 2025, volume 21 Issue: №2 Pages: 143-148
Heading: Ophthalmology Article type: Original article
Authors: Gusakov M.V., Kochergin S.A., Ovsyanko A.A.
Organization: Moscow City Ophthalmological Center of S. P. Botkin State Clinical Hospital of the Health Department of Moscow, Moscow, Russia
Heading: Ophthalmology Article type: Original article
Authors: Gusakov M.V., Kochergin S.A., Ovsyanko A.A.
Organization: Moscow City Ophthalmological Center of S. P. Botkin State Clinical Hospital of the Health Department of Moscow, Moscow, Russia
Summary:
Objective: to evaluate the relationship between blood clotting factor activity and the closure of full-thickness macular holes after surgical intervention using autologous conditioned plasma (ACP). Material and methods. A single-center retrospective cohort study was conducted involving 62 patients (62 eyes) with primary full-thickness macular holes. Patients underwent treatment: microinvasive subtotal vitrectomy with removal of epiretinal and internal limiting membranes, application of ACP, and airtamponade. Patients were divided into two groups: the main group (31 patients with coagulogram abnormalities) and the control group (31 patients with normal coagulogram parameters). Results. Surgical outcomes showed recurrence in 85.7% of cases in the main group versus 14.3% in controls (p=0.005). Among recurrence cases, 83.3% had prolonged prothrombin time (p=0.042) and 75.0% had reduced fibrinogen levels (p=0.049). Conclusion. Abnormalities in the coagulogram may be a risk factor for failure to close the macular rupture with ACP mass. Relapse was detected 6 times more often with an increase in prothrombin time, as well as with a decrease in fibrinogen below 2.0 g/L in the blood of patients.
Bibliography:
1. Forsaa VA, Lindtjorn В, Kvaloy JT, et al. Epidemiology and morphology of full-thickness macular holes. Acta Ophthal-mol. 2018;96(4):397-404. DOI:10.1111/aos.13618
2. Berco E, Tuli R, Sivachandran N, et al. Macular hole repair: The effect of size and nonsupine posture on postoperative outcomes. Digit J Ophthalmol. 2023;29(3):67-72. DOI:10.5693/djo.01.2023.05.001
3. Vaziri K, Schwartz SG, Kishor KS, et al. Rates of reoperation and retinal detachment after macular hole surgery. Ophthalmology. 2016;123(1 ):26-31. DOI:10.1016/j.ophtha. 2015.09.015
4. Shkvorchenko DO, Kakunina SA, Norman KS, et al. Surgical treatment of recurrent macular hole. Fyodorov Journal of Ophthalmic Surgery. 2023;3S:109-15.
5. Laviers Н, Papavasileiou Е, Bruce С, et al. The effect of ethnicity on anatomic success following macular hole surgery: A multicentre cohort study. Graefes Arch Clin Exp Ophthalmol. 2023;261 (6): 1535-43. DOI:10.1007/s00417-022-05950-w
6. Yue H, Liu C, Zhang Y, et al. Etiologies and clinical characteristics of macular hole: An 8-year, single-center, retrospective study. Medicine (Baltimore). 2024;103(32):e37878. DOI:10.1097/MD.0000000000037878
7. Yu Y, Qi B, Liang X, et al. Intraoperative iatrogenic retinal breaks in 23-gauge vitrectomy for stage 3 and stage 4 idiopathic macular holes. Br J Ophthalmol. 2021 ;105(1 ):93-6. DOI:10.1136/bjophthalmol-2019-315579
8. Chang JS, Smiddy WE. Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes. Ophthalmology. 2014;121(9):1720-6. DOM 0.1016/j.ophtha.2014.03.029
9. Parisi G, Gelormini F, Ricardi F, et al. Platelet rich plasma for primary macular hole: A case series. Eur J Ophthalmol. 2024;34(6): 1984-90. DOM0.1177/11206721241234419
10. Bikbov MM, Zainullin RM, Gilmanshin TR, et al. Platelet-rich autoplasma (ACP) — a new "tool" in macular surgery. Tochka zreniya. Vostok — Zapad. 2020;2:12.
11. Laskova IV, Kravchenko АА, Uskov Dl, et al. The use of autologous conditioned plasma (ACP) in the surgical treatment of full-thikness macular holes. Sovremennye tekhnologii v oftal'mologii. 2021;3:102-5.
12. Shkvorchenko DO, Zakharov VD, Krupina EA, et al. Surgical treatment of primary macular rupture using platelet-rich plasma. Fyodorov Journal of Ophthalmic Surgery. 2017;3:27-30.
13. Klatte-Schulz F, Schmidt Т, Uckert М, et al. Comparative analysis of different platelet lysates and platelet rich preparations to stimulate tendon cell biology: An in vitro study. Int J Mol Sci. 2018;19(1):212. DOI:10.3390/ijms19010212
14. Alshehri FSM, Whyte CS, Mutch NJ. Factor Xlll-A: An indispensable "factor" in haemostasis and wound healing. Int J Mol Sci. 2021 ;22(6):3055. DOI:10.3390/ijms22063055
15. Долгов В. В., Свирин П. В. Лабораторная диагностика нарушений гемостаза. М.; Тверь: Триада, 2005; 227 с.
16. Wu Z, Sun J, Liao Z, et al. Activation of PAR1 contributes to ferroptosis of Schwann cells and inhibits regeneration of myelin sheath after sciatic nerve crush injury in rats via Hippo-YAP/ACSL4 pathway. Exp Neurol. 2025;384:115053. DOM 0.1016/j.expneurol.2024.115053
17. Guo M, Zhu Y, Shi Y, et al. Inhibition of ferroptosis promotes retina ganglion cell survival in experimental optic neuropathies. Redox Biol. 2022;58:102541. DOM0.1016/J.redox. 2022.102541
18. Ruf W. Roles of factor Xa beyond coagulation. J Thromb Thrombolysis. 2021;52:391-6. DOI:10.1007/s1123 9-021-02458-8
19. Kazaykin VN, Demchenko NS, Kleimenov AYu. Optimization of platelet-rich plasma fraction selection for surgical treatment of macular holes. Ophthalmology in Russia. 2023;20 (4):664-74.
20. Jin G, Hayashi Т, Kawagoe J, et al. Deficiency of PAR-2 gene increases acute focal ischemic brain injury. J Cereb Blood Flow Metab.2005;25(3):302-13. DOM 0.1038/sj.jcbfm. 9600021
| Attachment | Size |
|---|---|
| 2025_02_143-148.pdf | 541.48 KB |
Русский
English